Quarterly ResultMay 6, 2026, 07:17 AM
X4 Pharmaceuticals Secures EU Approval for XOLREMDI; Q1 Net Loss $(20.2)M
AI Summary
X4 Pharmaceuticals reported its first-quarter 2026 financial results and provided a corporate update. The European Commission granted marketing authorization for XOLREMDI (mavorixafor) for WHIM syndrome in the EU, and the global 4WARD Phase 3 chronic neutropenia trial remains on track to complete enrollment by the end of Q3 2026. The company's cash position of $233.7 million as of March 31, 2026, provides a cash runway through 2028. For Q1 2026, X4 Pharmaceuticals reported a net loss of $(20.2) million on total revenue of $2.7 million, compared to a net income of $0.3 million on $28.8 million revenue in Q1 2025, primarily due to a one-time license revenue in the prior year.
Key Highlights
- European Commission granted marketing authorization for XOLREMDI (mavorixafor) for WHIM syndrome in the EU.
- Global 4WARD Phase 3 chronic neutropenia trial on track to complete enrollment by end of Q3 2026.
- Cash position was $233.7 million as of March 31, 2026, providing cash runway through 2028.
- Q1 2026 total revenue was $2.7 million, down from $28.8 million in Q1 2025.
- Q1 2026 net loss was $(20.2) million, or $(0.16) per share.
- Research and Development expenses decreased to $15.5 million in Q1 2026 from $18.5 million in Q1 2025.
- General and Administrative expenses decreased to $7.0 million in Q1 2026 from $15.0 million in Q1 2025.